* Mineralys Therapeutics Inc MLYS.OQ reported a quarterly
adjusted loss of $1.13 per share for the quarter ended
September 30, lower than the same quarter last year, when the
company reported EPS of -57 cents. The mean expectation of
seven analysts for the quarter was for a loss of 83 cents per
share. Wall Street expected results to range from -93 cents
to -66 cents per share.
* Reported revenue was zero; analysts expected zero.
* Mineralys Therapeutics Inc's reported EPS for the quarter
was a
loss of $1.13.
* The company reported a quarterly loss of $56.34 million.
* Mineralys Therapeutics Inc shares had risen by 15.9% this
quarter and gained 63.3% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 8.1%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Mineralys
Therapeutics Inc is 31.00
This summary was machine generated from LSEG data November 12 at
03:42 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.83 -1.13 Missed
Mar. 31 2024 -0.70 -0.83 Missed
Mar. 31 2024 -0.67 -0.70 Missed
Dec. 31 2023 -0.82 -0.61 Beat